Hyperkalaemia and potassium binders: Retrospective observational analysis looking at the efficacy and cost effectiveness of calcium polystyrene sulfonate and sodium zirconium cyclosilicate

Hyperkalaemia is a common medical emergency in patients admitted to hospital. There is a limited evidence base supporting some of the commonly applied treatment strategies. Although, NICE has recommended the use of sodium zirconium cyclosilicate (SZC) (TA599) and patiromer (TA623) in both acute and chronic hyperkalaemia, there is a limited evidence base for their use in acute hyperkalaemia in the hospital setting, particularly when compared to the present standard of care calcium polystyrene sulfonate (CPS).

[1]  Eunah Cheon,et al.  983: ACUTE HYPERKALEMIA: SODIUM ZIRCONIUM CYCLOSILICATE COMPARED TO SODIUM POLYSTYRENE SULFONATE , 2021, Critical Care Medicine.

[2]  C. Kovesdy,et al.  Consensus-Based Recommendations for the Management of Hyperkalemia in the Hemodialysis Setting. , 2021, Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation.

[3]  Dave L Dixon,et al.  Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis , 2021, Current therapeutic research, clinical and experimental.

[4]  P. Rossignol,et al.  Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program , 2021, Drugs - Real World Outcomes.

[5]  Shan Lin,et al.  Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis , 2021, Cardiovascular Drugs and Therapy.

[6]  P. Norman,et al.  Polysulfonate Resins in Hyperkalemia: A Systematic Review , 2020, Canadian journal of kidney health and disease.

[7]  W. Peacock,et al.  Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double‐blind, Placebo‐controlled Study (ENERGIZE) , 2020, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[8]  C. Minard,et al.  Patiromer for Treatment of Hyperkalemia in the Emergency Department: A Pilot Study. , 2019, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[9]  S. Grandy,et al.  Evidence in support of hyperkalaemia management strategies: A systematic literature review , 2018, International journal of clinical practice.

[10]  Jiwei Zhao,et al.  Systematic Review and Meta‐Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia , 2017, Pharmacotherapy.

[11]  Josh Batterink,et al.  Pharmacological interventions for the acute management of hyperkalaemia in adults. , 2015, The Cochrane database of systematic reviews.

[12]  Y. Oh,et al.  Severe hyperkalemia requiring hospitalization: predictors of mortality , 2012, Critical Care.

[13]  Joann L. Baril,et al.  Nursing Time Devoted to Medication Administration in Long‐Term Care: Clinical, Safety, and Resource Implications , 2009, Journal of the American Geriatrics Society.

[14]  R. Kirkman,et al.  Intestinal necrosis associated with postoperative orally administered sodium polystyrene sulfonate in sorbitol. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  B. Paice,et al.  Hyperkalaemia in patients in hospital. , 1983, British medical journal.